AMIT PAI is an Associate Professor of Clinical Pharmacy with expertise in precision dosage regimen design. He has extensive training in clinical pharmacology and drug development, with specific expertise in clinical pharmacokinetics/pharmacodynamics (PK/PD). His experiences span from  in vitro studies to characterize antifungal pharmacodynamics, pre-clinical studies to evaluate toxicology, use of semi-invasive and non-invasive methods to characterize drug biodistribution, to the translation of these findings to design novel formulations to optimize PK/PD. During his first academic appointment, he completed a 2-year general clinical research center scholars program followed by a 2-year clinical translational science center (KL2) scholars program. His research expertise includes application of population PK Modeling  to advocate for changes to current drug dosing paradigms.

He also currently serves as the Deputy Director of the PK Core that is a shared resource for the University of Michigan.  (www.pkcore.org). This resource maintains six mass spectrometers including two newly acquired state-of-the-art instruments to support high resolution mass spectrometry and imaging mass spectrometry (DESI and MALDI based applications). This Mass spectrometry and Pharmacokinetics core has dedicated analytical chemistry staff, in vivo pre-clincial staff, and clinical research staff to support drug discovery and development.

His research focus is the design of optimal dosing regimens across the modern adult and pediatric body weight distribution (1-250 kg). He has served as the PI on six clinical trials dedicated to the evaluation of the PK/PD of antimicrobials in obesity and has developed PK models for 20 compounds in this special population. These works have propelled his understanding and passion for the design of safer and more effective treatment regimens in special populations, who are often excluded during drug development.

 

Optimization of empiric dosage selection through pharmacokinetic / pharmacodynamic analyses in special populations who are underrepresented in clinical drug development.
 
MODERN DAY POSOLOGY!

Listing Row

Wednesday, September 14, 2016
Wednesday, September 14, 2016